PLTR stock slid to trade at $8.05 as of 12:27 PM EDT.
A completely integrated medical supply chain ecosystem will be powered by a collaboration between Concordance Healthcare Solutions and operating systems business Palantir Technologies (NYSE:PLTR). The ecosystem, which is a pioneer in its field, integrates inventory and supply chain data from producers, suppliers, distributors, and providers into a single, seamless, real-time system.
In order to provide a single, agnostic point of reference, the two businesses want to create an ecosystem that can handle various data sets and various enterprise resource planning systems, regardless of compatibility.
Any healthcare manufacturer, supplier, distributor, provider, or government public health agency with a license has access to the ecosystem, which already has active participants.
PLTR stock was up 0.25 percent pre-market.
The manufacturer and provider communities already have active participants who can access the ecosystem with a license. The ecosystem’s development is currently primarily concentrated on the fundamental supply chain issues that the sector faces, boosting visibility upstream and downstream to provide users with real-time information and data that enables them to make quicker, more educated decisions. In the future, we want to expand the ecosystem with new workflows and logic to investigate the problems with the healthcare supply chain, which frequently go beyond issues with supply. Currently, Palantir’s software is being used throughout the whole healthcare value chain and beyond, in fields such as life sciences, pharma, biotech, clinical research, and healthcare operations, to help inform better decisions about the most difficult issues facing the globe.
PLTR stock outlook
In September 2020, Palantir (NYSE: PLTR) went public at a price of $10 per share. The price of Palantir stock increased to $45 by January 2021. That proved to be a record-breaking high. The current price is approximately $7.8 after falling over time.
Any investor who purchased Palantir must feel let down so far. However, given that I could currently purchase shares of the firm for less than its IPO price, I believe it is worthwhile to explore if I should include it in my portfolio.
Featured Image – Unsplash © emilep